Aripiprazole for patients with schizophrenia and schizoaffective disorder: An open-label, randomized, study versus haloperidol

CNS Spectrums

Volumn 14, Issue 2, 2009, Pages 93-102

  de Oliveira, Irismar Reis ^a   Elkis, Hélio ^b   Gattaz, Wagner Farid ^b   Chaves, Ana Cristina ^c   Sena, de Eduardo Pondé ^a   Souza, Fabio Gomes de Matos ^d   Campos, João Alberto ^e   Bueno, João Romildo ^f   Silva, Jorge Alberto Costa ^g   Louzã, Mário Rodrigues ^c   de Abreu, Paulo Belmonte ^h  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^e FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^f FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^g STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^h HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; BENZODIAZEPINE; HALOPERIDOL; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; AGED; AGGRESSION; AKATHISIA; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HOSTILITY; HUMAN; INSOMNIA; LIMB TREMOR; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PHASE 4 CLINICAL TRIAL; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; MIDDLE AGED; PSYCHOSIS; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PSYCHOTIC DISORDERS; QUINOLONES; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 63349093738     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900000249     Document Type: Article

References (43)

1. De Oliveira IR, Juruena MF. Treatment of psychosis: 30 years of progress. J Clin Pharm Ther 2006;31:523-534.
2. Tandon R, Belmaker RH, Gattaz WF, et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 2008;100:20-38.
3. Goff DC, Evins AE. Negative symptoms in schizophrenia: neurobiological models and treatment response. Harv Rev Psychiatry 1998;6:59-77.
4. Siris SG. Depression in schizophrenia: perspective in the era of "atypical" antipsychotic agents. Am J Psychiatry. 2000;157:1379-1389.
5. Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull. 1999;25:201-222.
6. Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl). 1989;99(suppl):S18-S27.
7. Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci 2000;25:161-166.
8. Lahti AC, Weiler MA, Corey PK, Lahti RA, Carlsson A, Tamminga CA. Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclam ol) in schizophrenia. Biol Psychiatry. 1998;43:2-11.
9. Naber D, Lambert M. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:1213-1219.
10. Kikuchi T, Tottori K, Uwahodo Y, et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 1995;274:329-336.
11. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302:381-389.
12. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002;441:137-140.
13. Hirose T, Uwahodo Y, Yamada S, et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol. 2004;18:375-383.
14. Sovner R, Parnell-Sovner N. Use of buspirone in the treatment of schizophrenia. J Clin Psychopharmacol 1989;9:61-62.
15. Millan MJ. Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors. J Pharmacol Exp Ther 2000;295:853-861.
16. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry. 1999;60(suppl 10):5-14.
17. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63:763-771.
18. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003;60:681-690.
19. Tandon R, Marcus RN, Stock EG, et al. A prospective, multicenter, randomized, parallelgroup, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophr Res 2006;84:77-89.
20. Cutler AJ, Marcus RN, Hardy SA, O'Donnel A, Carson WH, McQuade RD. The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia. CNS Spectr. 2006;11:691-702.
21. McEvoy JP, Daniel DG, Carson WH Jr, McQuade RD, Marcus RN. A randomized, doubleblind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res. 2007;41:895-905.
22. Wolf J, Janssen F, Lublin H, et al. A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA). Curr Med Res Opin. 2007;23:2313-2323.
23. Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG; Aripiprazole Study Group. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64:1048-1056.
24. Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Nt J Neuropsychopharmacol. 2003;6:325-337.
25. Chan HY, Lin WW, Lin SK, et al. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. J Clin Psychiatry. 2007;68:29-36.
26. Kane JM, Meltzer HY, Carson WH Jr, McQuade RD, Marcus RN, Sanchez R; The Aripiprazole Study Group. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry. 2007;68:213-223.
27. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123-136.
28. Chaves AC, Seeman MV. Sex selection bias in schizophrenia antipsychotic trials. J Clin Pshychopharmacol. 2006;26:489-494.
29. Kerwin R, Millet B, Herman E, et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. Eur Psychiatry 2007;22:433-443.
30. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text rev. Washington, DC: American Psychiatric Association; 2000.
31. Kay, SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophr Bull. 1987;13:261-276.
32. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatric Res. 1988;23:99-110.
33. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000;321:1371-1376.
34. Guy W. ECDEU Assessment Manual for Psychopharmacology: Revised (DHEW Publication No. ADM 76-338) Rockville, Md: National Institute of Mental Health; 1976.
35. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-483.
36. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand. 1970;45(suppl 212):11-19.
37. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
38. Lingjaerde O, Ahlfors UG, Bech P. The UKU Side-Effect Rating Scale. Acta Psychiatr Scand 1987;76(suppl 334):81-94.
39. Moher D, Schulz KF, Altman D; CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285:1987-1991.
40. Leucht S, Pitchel-Walz G, Engel RR, Kissling W. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002;159:180-190.
41. Marder SR, West B, Lau GS, et al. Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials. J Clin Psychiatry. 2007;68:662-668.
42. Rosa AR, Sanchez-Moreno J, Martinez-Aran A, et al. Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder. Clin Pract Epidemol Ment Health. 2007;3:5.
43. Shimoda K, Someya T, Morita S, et al. Lower plasma levels of haloperidol in smoking than in nonsmoking schizophrenic patients. Ther Drug Monit. 1999;21:293-296.